Spine Biologics Market Report by Product (Spinal Allografts, Bone Graft Substitutes, Cell Based Matrix), Surgery Type (Open Spine Surgery, Minimally Invasive Spine Surgery), End User (Hospitals, Ambulatory Care Centers, Spinal Surgery Centers, Orthopedic

Spine Biologics Market Report by Product (Spinal Allografts, Bone Graft Substitutes, Cell Based Matrix), Surgery Type (Open Spine Surgery, Minimally Invasive Spine Surgery), End User (Hospitals, Ambulatory Care Centers, Spinal Surgery Centers, Orthopedic Clinics, and Others), and Region 2024-2032

The global spine biologics market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is driven by the widespread adoption of minimally invasive surgeries (MIS), the growing geriatric population, the growing access to healthcare services on account of inflating income levels, and the increasing incidence of spinal disorders.

Spine Biologics Market Analysis:

• Major Market Drivers: The spine biologics market research indicates that the market is primarily driven by the increasing prevalence of spinal disorders such as disc disease and spinal stenosis, often related to aging and lifestyle factors.
• Key Market Trends: There is a noticeable trend toward the use of biologics in spine surgeries to promote quicker recovery and better outcomes, aligning with advancements in medical technologies. In the spine biologics market forecast, the industry will witness ongoing innovation with the integration of artificial intelligence and machine learning technologies to enhance the precision and effectiveness of spine biologics.
• Geographical Trends: North America currently leads the global market due to its advanced healthcare infrastructure, high healthcare expenditure, and awareness of spinal ailments. Moreover, the Asia-Pacific region is witnessing rapid growth according to the spine biologics market statistics owing to increasing healthcare access, rising economic standards, and a growing geriatric population.
• Competitive Landscape: Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet, among many others.
• Challenges and Opportunities: The challenges in the market include concerns over the high cost of biologic products and stringent regulatory environments that can delay product launches. As outlined in the spine biologics market overview, the growing collaborations with insurance providers and healthcare facilities hold the potential to improve access to and uptake of biologic treatments generating numerous opportunities.

Spine Biologics Market Trends:

Increasing Prevalence of Spinal Disorders

The growing occurrence of spinal disorders is affecting the spine biologics market growth. In addition, the increasing life expectancy, and lifestyle issues, are spurring the development of degenerative illnesses such as disc disease and spinal stenosis. According to the World Health Organization (WHO) in 2020 approximately 1 in 13 individuals equating to 619 million individuals experienced low back pain (LBP), a 60% increase from 1990. It is further estimated that low back pain cases will increase by around 843 million by 2050 which emphasizes the widespread nature of spinal issues. The rising number of incidences is with the age group of 80 years, and the increasing number of LBP cases occur at the age of 50-55 years. This widespread prevalence necessitates ongoing development and deployment of effective treatments, including biologics, which help promote bone growth and healing, making them critical in treating these pervasive conditions.

Rising Adoption of Minimally Invasive Surgeries (MIS)

Minimally invasive surgeries (MIS) for spinal conditions are preferred due to their less distressful nature and quicker recovery times compared to traditional open surgeries. The global market for minimally invasive surgery is projected to expand at a compound annual growth rate (CAGR) of roughly 6% during 2024-2032 as per the IMARC GROUP. It reached US$ 52.9 Billion in 2023 and anticipates the market to reach US$ 91.0 Billion by 2032. This growth is declarative of a shift in surgical methods that reduce hospital stays and recovery periods, which is particularly beneficial for spine biologics market value.

Growing Geriatric Population

The growing geriatric population is driving the spine biologics market demand. As individuals age, the risk of developing spinal disorders increases, necessitating more frequent and intensive care. As per the data from the UNITED NATIONS population aged 65 and over is expected to rise from 10% in 2022 to 16% in 2050. It is forecasted that individuals aged 65 years or above globally will double the number of children under age 5 and will be equal to the number of 12-year-old children. It means a rising number of age-associated spinal conditions, escalating the demand for treatments that are effective and minimally invasive. For instance, biologics, which aid in the natural healing processes, are particularly suited to meet these needs, aligning with the growing healthcare requirements of an aging global population.

Spine Biologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, surgery type, and end user.

Breakup by Product:

• Spinal Allografts
• Machined Bones Allograft
• Demineralized Bone Matrix
• Bone Graft Substitutes
• Bone Morphogenetic Proteins
• Synthetic Bone Grafts
• Cell Based Matrix

Bone graft substitutes account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes spinal allografts (machined bones allograft, demineralized bone matrix), bone graft substitutes, (bone morphogenetic proteins, synthetic bone grafts), and cell-based matrix. According to the report, bone graft substitutes represented the largest segment.

Bone graft substitutes offer an alternative to customary bone grafts, stipulating structural support and facilitating bone healing processes in spinal surgeries. These substitutes embrace synthetic materials, allografts, and demineralized bone matrix, and are advocated for their aptitude to endorse bone fusion and curb the need for harvesting bone from the patient's own body, minimizing surgical complications and recovery time. As per the statistics by IMARC GROUP, the global bone graft and substitute market reached US$3.2 Billion in 2023. It is estimated to reach US$ 5.1 Billion by 2032 with a compound annual growth rate (CAGR) of 5.2% during 2024-2032. Moreover, various advancements in biomaterials, regenerative medicine, and bone graft substitutes are witnessing increasing adoption in spinal procedures, thus positively increasing the spine biologic market value.

Breakup by Surgery Type:

• Open Spine Surgery
• Minimally Invasive Spine Surgery

Minimally invasive spine surgery holds the largest share of the industry

A detailed breakup and analysis of the market based on the surgery type have also been provided in the report. This includes open spine surgery and minimally invasive spine surgery. According to the report, minimally invasive spine surgery accounted for the largest market share.

Minimally invasive spine surgery is primarily attributed to the growing preference for minimally invasive procedures among patients and healthcare providers. Minimally invasive spine surgery offers several advantages over traditional open surgeries, including smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times. As a result, it has gained popularity for treating various spinal conditions, such as degenerative disc disease, herniated discs, spinal stenosis, and vertebral fractures. According to the NATIONAL LIBRARY OF MEDICINE, minimally invasive spine (MIS) surgery has advanced significantly with imaging navigation systems, robotics, and endoscopy. More than 400,000 cases are accomplished in the United States annually with spine fusion being the commonly conducted and established treatment options for spine trauma, tumors, structural deformities, and degenerative disorders.

Breakup by End User:

• Hospitals
• Ambulatory Care Centers
• Spinal Surgery Centers
• Orthopedic Clinics
• Others

Hospitals represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory care centers, spinal surgery centers, orthopedic clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals are major centers for specialized medical care that attract a considerable proportion of patients seeking treatments for several forms of spinal disorders including those that necessitate surgeries. Furthermore, some hospitals have dedicated spine centers or departments where they offer services, making them the preferred centers for comprehensive source care. Besides this, hospitals have strong collaborations with spine biologic manufacturers and suppliers, thereby enhancing the efficiency of the equipment. In June 2022, Xenco Medical broadened its range of devices for ambulatory surgery centers by securing Food and Drug Administration (FDA) clearance and introducing its Multilevel CerviKit for their single use. It comprises a complete suite of implants and single-use instruments for two, three, and four level procedures of the anterior cervical spine.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America leads the market, accounting for the largest spine biologics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for spine biologics.

North America’s dominance in the market can be attributed to highly developed healthcare infrastructure, the high rate of innovative medical technologies’ adoption, and a large patient pool with spinal disorders. For instance, as per the data from the National Spinal Cord Injury Association, approximately 450,000 individuals reside in the United States with a spinal cord injury (SCI). Annually, an estimated 17,000 new cases of SCI arise in the U.S., predominantly stemming from trauma to the vertebral column. Thus, the increasing incidence of SCI population is significantly escalating the demand for spine biologics to treat disorders across the region. Additionally, favorable reimbursement policies, strong R&D efforts, and awareness of the advantages of minimally invasive surgical procedures are generating the spine biologics market revenue in North America.

Competitive Landscape:

• The spine biologics market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

At present, key players in the market are investing in research and innovation to develop models that outperform rivals and offer solutions sought by customers. They also work hard to ensure their products remain in the market and meet customers' demands through the development of strategic alliances, acquisitions, and expansions into new markets to penetrate more markets and meet all customer needs. For instance, in October 2023, Orthofix Medical Inc., a prominent global spine and orthopedics corporation unveiled the full commercial release of OsteoCove, which is an innovative bioactive synthetic graft, following its 510k clearance. It is offered in putty and strip forms, meticulously developed to offer exceptional bone-forming capabilities and optimal handling properties for various spine and orthopedic procedures. Moreover, excellent marketing and brand management also make their products highly demanded, which is providing a positive spine biologics market outlook.

Spine Biologics Market News:

• August 2022: Graftys SA announced the renewal of its lengthy contract with Arthrex for a multi-year supply agreement concerning advanced synthetic bone graft materials.
• October 2023: Stryker, a prominent medical technology company unveiled their Q guidance system with spine guidance software which was deployed to supply improved surgical planning and navigation in over 2,400 spinal cases.

Key Questions Answered in This Report

1. How big is the global spine biologics market?

2. What is the expected growth rate of the global spine biologics market during 2024-2032?

3. What are the key factors driving the global spine biologics market?

4. What has been the impact of COVID-19 on the global spine biologics market?

5. What is the breakup of the global spine biologics market based on the product?

6. What is the breakup of the global spine biologics market based on the surgery type?

7. What is the breakup of the global spine biologics market based on the end user?

8. What are the key regions in the global spine biologics market?

9. Who are the key players/companies in the global spine biologics market?